Re:Preempt (Canada) efficacy against Monkeypox Virus (MPV)

To Whom it May Concern,

In cases of emerging viral pathogens such as Monkeypox Virus (MPV), when there is no test that can be conducted to validate the efficacy of a disinfectant, Health Canada utilizes its policy for claims against emerging viral pathogens to determine the expected efficacy of a disinfectant against an emerging virus. Per this policy, DIN-approved disinfectants which have received market authorization for a “broad spectrum virucide” claim (i.e., have proven efficacy against a hard-to-kill non-enveloped virus) or a specific claim against a non-enveloped virus are expected to inactivate less resistant enveloped viruses, such as MPV.

The Preempt line of disinfectants fulfill these criteria and therefore can be used against MPV on hard, non-porous surfaces as part of a facility’s infection prevention and control protocols:

• Preempt Concentrate (DIN 02436701) should be applied at a 1:40 dilution for a contact time of five minutes.
• Preempt Ready-to-Use (RTU) (DIN 02436698) and Preempt Wipes (DIN 02436671) should be applied with a three-minute contact time.

To learn more about this ongoing situation as it unfolds, please refer to Health Canada’s information page at the following link: https://www.canada.ca/en/public-health/services/diseases/monkeypox.html.

Should you require any further information, please do not hesitate to contact us at 1-800-387-7578. Best

regards,

Junette D. Tabadero

Director, Regulatory Affairs Virox Technologies Inc.